Healthcare >> CEO Interviews >> September 14, 2001
GEORGE A. SCANGOS joined Exelixis, Inc., as President and Chief
Executive Officer in October 1996 from Bayer Corporation. At
Bayer, he held several positions, including Senior Vice President
of Research and Development for Bayer's pharmaceutical division,
and then President of Bayer Biotechnology. As President of Bayer
Biotechnology, Dr. Scangos was responsible for 1,100 employees in
research and development, business development, process
development, manufacturing, engineering, and quality assurance.
Prior to Bayer, Dr. Scangos was on the faculty of The Johns
Hopkins University where he now holds an appointment as Adjunct
Professor of Biology. He serves on the Board of Visitors at the
University of California, San Francisco School of Pharmacy, the
Board of Overseers at the University of California, Davis Medical
School, and the Boards of Directors at Entelos, Inc., Onyx
Pharmaceuticals, and Exelixis. Dr. Scangos holds a PhD in
Microbiology from the University of Massachusetts, and was a Jane
Coffin Childs Postdoctoral Fellow. Profile
Exelixis?
Dr. Scangos: Exelixis was founded in 1995. It began life as a functional
genomics company with a particular
